363 related articles for article (PubMed ID: 17982656)
1. Expression of the serum response factor in hepatocellular carcinoma: implications for epithelial-mesenchymal transition.
Park MY; Kim KR; Park HS; Park BH; Choi HN; Jang KY; Chung MJ; Kang MJ; Lee DG; Moon WS
Int J Oncol; 2007 Dec; 31(6):1309-15. PubMed ID: 17982656
[TBL] [Abstract][Full Text] [Related]
2. Signal transducers and activators of transcription 5b activation enhances hepatocellular carcinoma aggressiveness through induction of epithelial-mesenchymal transition.
Lee TK; Man K; Poon RT; Lo CM; Yuen AP; Ng IO; Ng KT; Leonard W; Fan ST
Cancer Res; 2006 Oct; 66(20):9948-56. PubMed ID: 17047057
[TBL] [Abstract][Full Text] [Related]
3. A peroxisome proliferator-activated receptor gamma antagonist induces vimentin cleavage and inhibits invasion in high-grade hepatocellular carcinoma.
Kim KR; Choi HN; Lee HJ; Baek HA; Park HS; Jang KY; Chung MJ; Moon WS
Oncol Rep; 2007 Oct; 18(4):825-32. PubMed ID: 17786342
[TBL] [Abstract][Full Text] [Related]
4. Serum response factor induces epithelial to mesenchymal transition with resistance to sorafenib in hepatocellular carcinoma.
Bae JS; Noh SJ; Kim KM; Jang KY; Chung MJ; Kim DG; Moon WS
Int J Oncol; 2014 Jan; 44(1):129-36. PubMed ID: 24173109
[TBL] [Abstract][Full Text] [Related]
5. Serum response factor depletion affects the proliferation of the hepatocellular carcinoma cells HepG2 and JHH6.
Farra R; Dapas B; Pozzato G; Giansante C; Heidenreich O; Uxa L; Zennaro C; Guarnieri G; Grassi G
Biochimie; 2010 May; 92(5):455-63. PubMed ID: 20144681
[TBL] [Abstract][Full Text] [Related]
6. The role of serum response factor in hepatocellular carcinoma: an association with matrix metalloproteinase.
Kim KR; Bae JS; Choi HN; Park HS; Jang KY; Chung MJ; Moon WS
Oncol Rep; 2011 Dec; 26(6):1567-72. PubMed ID: 21842128
[TBL] [Abstract][Full Text] [Related]
7. Block of proliferation 1 (BOP1) plays an oncogenic role in hepatocellular carcinoma by promoting epithelial-to-mesenchymal transition.
Chung KY; Cheng IK; Ching AK; Chu JH; Lai PB; Wong N
Hepatology; 2011 Jul; 54(1):307-18. PubMed ID: 21520196
[TBL] [Abstract][Full Text] [Related]
8. The expression and role of serum response factor in papillary carcinoma of the thyroid.
Kim HJ; Kim KR; Park HS; Jang KY; Chung MJ; Shong M; Moon WS
Int J Oncol; 2009 Jul; 35(1):49-55. PubMed ID: 19513551
[TBL] [Abstract][Full Text] [Related]
9. Serum response factor enhances liver metastasis of colorectal carcinoma via alteration of the E-cadherin/beta-catenin complex.
Choi HN; Kim KR; Lee JH; Park HS; Jang KY; Chung MJ; Hwang SE; Yu HC; Moon WS
Oncol Rep; 2009 Jan; 21(1):57-63. PubMed ID: 19082443
[TBL] [Abstract][Full Text] [Related]
10. The role of serum response factor in hepatocellular carcinoma: implications for disease progression.
Kwon CY; Kim KR; Choi HN; Chung MJ; Noh SJ; Kim DG; Kang MJ; Lee DG; Moon WS
Int J Oncol; 2010 Oct; 37(4):837-44. PubMed ID: 20811705
[TBL] [Abstract][Full Text] [Related]
11. N-cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma.
Nakajima S; Doi R; Toyoda E; Tsuji S; Wada M; Koizumi M; Tulachan SS; Ito D; Kami K; Mori T; Kawaguchi Y; Fujimoto K; Hosotani R; Imamura M
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4125-33. PubMed ID: 15217949
[TBL] [Abstract][Full Text] [Related]
12. Epithelial-mesenchymal transition in ovarian cancer progression: a crucial role for the endothelin axis.
Bagnato A; Rosanò L
Cells Tissues Organs; 2007; 185(1-3):85-94. PubMed ID: 17587812
[TBL] [Abstract][Full Text] [Related]
13. [Selective deposition of agrin in the microvasculature of hepatocellular carcinoma: aspects in pathogenesis and differential diagnosis].
Tátrai P
Magy Onkol; 2008 Dec; 52(4):379-83. PubMed ID: 19068466
[TBL] [Abstract][Full Text] [Related]
14. Fascin-1 expression correlates with repression of E-cadherin expression in hepatocellular carcinoma cells and augments their invasiveness in combination with matrix metalloproteinases.
Hayashi Y; Osanai M; Lee GH
Cancer Sci; 2011 Jun; 102(6):1228-35. PubMed ID: 21323792
[TBL] [Abstract][Full Text] [Related]
15. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines.
Yang AD; Fan F; Camp ER; van Buren G; Liu W; Somcio R; Gray MJ; Cheng H; Hoff PM; Ellis LM
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4147-53. PubMed ID: 16857785
[TBL] [Abstract][Full Text] [Related]
16. CD44s regulates the TGF-β-mediated mesenchymal phenotype and is associated with poor prognosis in patients with hepatocellular carcinoma.
Mima K; Okabe H; Ishimoto T; Hayashi H; Nakagawa S; Kuroki H; Watanabe M; Beppu T; Tamada M; Nagano O; Saya H; Baba H
Cancer Res; 2012 Jul; 72(13):3414-23. PubMed ID: 22552294
[TBL] [Abstract][Full Text] [Related]
17. [Expression of CXCR3 in hepatocellular carcinoma].
Shi M; Guo RP; Zhang CQ; Zhong C; Lin XJ; Li JQ
Ai Zheng; 2006 Oct; 25(10):1232-7. PubMed ID: 17059766
[TBL] [Abstract][Full Text] [Related]
18. Loss of claudin-1 expression correlates with malignancy of hepatocellular carcinoma.
Higashi Y; Suzuki S; Sakaguchi T; Nakamura T; Baba S; Reinecker HC; Nakamura S; Konno H
J Surg Res; 2007 May; 139(1):68-76. PubMed ID: 17270214
[TBL] [Abstract][Full Text] [Related]
19. ASPM is a novel marker for vascular invasion, early recurrence, and poor prognosis of hepatocellular carcinoma.
Lin SY; Pan HW; Liu SH; Jeng YM; Hu FC; Peng SY; Lai PL; Hsu HC
Clin Cancer Res; 2008 Aug; 14(15):4814-20. PubMed ID: 18676753
[TBL] [Abstract][Full Text] [Related]
20. Bone morphogenetic protein 4 is induced in hepatocellular carcinoma by hypoxia and promotes tumour progression.
Maegdefrau U; Amann T; Winklmeier A; Braig S; Schubert T; Weiss TS; Schardt K; Warnecke C; Hellerbrand C; Bosserhoff AK
J Pathol; 2009 Aug; 218(4):520-9. PubMed ID: 19431154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
